1. Pink Sheet
  2. >>Compliance
  3. >>Manufacturing

The ICH Plans To Propose Q14 Guideline On Analytical Testing In January

 
• By Joanne S. Eglovitch

The ICH is expected to release for public comment early next year its draft Q14 guideline establishing a lifecycle approach for analytical testing, as well as a Q2(R2) guideline to add some newer analytical methods.

Portable Raman Spectrometer
ICH To Soon Modernize Analytical Testing Guidelines • Source: Shutterstock

The International Council on Harmonization is expected to propose for public consultation a guideline that establishes a lifecycle approach to analytical method validation in January 2021, said a member of the ICH expert working group that is developing the Q14 guideline.

The expert working group also plans to release another ICH guideline, Q2(R2), that establishes newer analytical procedures such as near-infrared (NIR) spectroscopy and Raman spectroscopy, and to issue this draft...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Compliance

Pharma DTC Ad Tax Break Targeted By US HHS, Congress

 
• By Derrick Gingery

Health and Human Services Secretary Robert F. Kennedy Jr. said a policy that would remove the tax write-off for pharma advertising expenses would be coming in a few weeks.

Sarfez Pharma’s Promotional Claims For Diuretic Soaanz Draw US FDA Warning Letter

 
• By Sue Sutter

Webpages, a healthcare professional pamphlet and a medical conference exhibit booth panel make unsupported comparative superiority claims about generic torsemide products and misrepresent risks, the Office of Prescription Drug Promotion says in its first warning letter of 2025.

US FDA Legislative Lead Calls For User Fee Reforms As Renewal Talks Near

 
• By Sarah Karlin-Smith

Deputy FDA Commissioner Grace Graham acknowledged the importance of user fees, while also calling for restructuring. She also said part of MAHA's mission is to reexamine uses of drugs not supported by data.